DarioHealth Corp. (DRIO)
USD 0.72
(29.66%)
USD 0.72
(29.66%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -7.54 Million USD | 64.58% |
| 2022 | -21.3 Million USD | 40.01% |
| 2021 | -35.52 Million USD | -26.6% |
| 2020 | -28.05 Million USD | -42.99% |
| 2019 | -19.62 Million USD | -78.44% |
| 2018 | -10.99 Million USD | -195.78% |
| 2017 | -3.71 Million USD | -240.16% |
| 2016 | -1.09 Million USD | -248.09% |
| 2015 | -314 Thousand USD | -124.08% |
| 2014 | 1.3 Million USD | 157.61% |
| 2013 | -2.26 Million USD | -84.01% |
| 2012 | -1.23 Million USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 6.83 Million USD | 239.42% |
| 2024 Q1 | -4.9 Million USD | 35.04% |
| 2023 Q4 | -7.54 Million USD | 45.91% |
| 2023 FY | -7.54 Million USD | 64.58% |
| 2023 Q1 | -12.41 Million USD | 41.72% |
| 2023 Q3 | -13.95 Million USD | 37.92% |
| 2023 Q2 | -22.47 Million USD | -81.0% |
| 2022 Q2 | -44.69 Million USD | 19.17% |
| 2022 Q3 | -31.94 Million USD | 28.53% |
| 2022 Q4 | -21.3 Million USD | 33.3% |
| 2022 FY | -21.3 Million USD | 40.01% |
| 2022 Q1 | -55.29 Million USD | -55.68% |
| 2021 Q3 | -50.97 Million USD | 19.64% |
| 2021 Q1 | -80.67 Million USD | -187.52% |
| 2021 Q4 | -35.52 Million USD | 30.31% |
| 2021 Q2 | -63.42 Million USD | 21.37% |
| 2021 FY | -35.52 Million USD | -26.6% |
| 2020 FY | -28.05 Million USD | -42.99% |
| 2020 Q1 | -15.15 Million USD | 22.77% |
| 2020 Q2 | -12.57 Million USD | 17.02% |
| 2020 Q3 | -36.36 Million USD | -189.15% |
| 2020 Q4 | -28.05 Million USD | 22.84% |
| 2019 Q2 | -7.2 Million USD | -17.24% |
| 2019 FY | -19.62 Million USD | -78.44% |
| 2019 Q3 | -3.82 Million USD | 46.93% |
| 2019 Q4 | -19.62 Million USD | -413.56% |
| 2019 Q1 | -6.14 Million USD | 44.16% |
| 2018 Q2 | -5.01 Million USD | 28.83% |
| 2018 Q1 | -7.04 Million USD | -89.38% |
| 2018 FY | -10.99 Million USD | -195.78% |
| 2018 Q4 | -10.99 Million USD | 3.76% |
| 2018 Q3 | -11.42 Million USD | -128.04% |
| 2017 Q4 | -3.71 Million USD | 40.63% |
| 2017 FY | -3.71 Million USD | -240.16% |
| 2017 Q1 | -2.81 Million USD | -157.73% |
| 2017 Q2 | -3.89 Million USD | -38.37% |
| 2017 Q3 | -6.26 Million USD | -60.65% |
| 2016 Q3 | -3.33 Million USD | 47.63% |
| 2016 Q4 | -1.09 Million USD | 67.27% |
| 2016 FY | -1.09 Million USD | -248.09% |
| 2016 Q2 | -6.37 Million USD | 22.87% |
| 2016 Q1 | -8.26 Million USD | -2558.2% |
| 2015 FY | -314 Thousand USD | -124.08% |
| 2015 Q4 | -311 Thousand USD | -168.81% |
| 2015 Q3 | 452 Thousand USD | -67.22% |
| 2015 Q2 | 1.37 Million USD | 71.3% |
| 2015 Q1 | 805 Thousand USD | -38.41% |
| 2014 Q1 | -3.81 Million USD | -68.42% |
| 2014 FY | 1.3 Million USD | 157.61% |
| 2014 Q4 | 1.3 Million USD | -18.82% |
| 2014 Q3 | 1.61 Million USD | 188.51% |
| 2014 Q2 | -1.81 Million USD | 52.28% |
| 2013 Q2 | -7.02 Million USD | -2282.28% |
| 2013 Q1 | -294.89 Thousand USD | 76.03% |
| 2013 FY | -2.26 Million USD | -84.01% |
| 2013 Q3 | -4.46 Million USD | 36.4% |
| 2013 Q4 | -2.26 Million USD | 49.34% |
| 2012 FY | -1.23 Million USD | 0.0% |
| 2012 Q4 | -1.23 Million USD | -50.0% |
| 2012 Q3 | -820.01 Thousand USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Aclaris Therapeutics, Inc. | -39.45 Million USD | 80.868% |
| Applied DNA Sciences, Inc. | -5.91 Million USD | -27.628% |
| Aspira Women's Health Inc. | -331 Thousand USD | -2180.363% |
| Biodesix, Inc. | 34.3 Million USD | 122.001% |
| BioNexus Gene Lab Corp. | -5.79 Million USD | -30.229% |
| bioAffinity Technologies, Inc. | -1.24 Million USD | -507.274% |
| bioAffinity Technologies, Inc. | -1.24 Million USD | -507.274% |
| Bionano Genomics, Inc. | 34.88 Million USD | 121.639% |
| CareDx, Inc | -47.97 Million USD | 84.267% |
| Check-Cap Ltd. | -24.75 Million USD | 69.51% |
| Castle Biosciences, Inc. | -83.53 Million USD | 90.964% |
| Exact Sciences Corporation | 1.94 Billion USD | 100.387% |
| Fulgent Genetics, Inc. | -82.56 Million USD | 90.858% |
| Guardant Health, Inc. | 220.22 Million USD | 103.427% |
| ICON Public Limited Company | 3.56 Billion USD | 100.212% |
| IDEXX Laboratories, Inc. | 493.94 Million USD | 101.528% |
| Illumina, Inc. | 1.21 Billion USD | 100.622% |
| Intelligent Bio Solutions Inc. | -5.43 Million USD | -38.938% |
| iSpecimen Inc. | -2.14 Million USD | -251.491% |
| Standard BioTools Inc. | 46.5 Million USD | 116.23% |
| MDxHealth SA | 18.88 Million USD | 139.968% |
| 23andMe Holding Co. | -141.37 Million USD | 94.661% |
| Medpace Holdings, Inc. | -103.32 Million USD | 92.695% |
| Myriad Genetics, Inc. | 88.1 Million USD | 108.568% |
| Mainz Biomed B.V. | 349.85 Thousand USD | 2257.465% |
| ENDRA Life Sciences Inc. | -2.43 Million USD | -209.407% |
| NeoGenomics, Inc. | 269.19 Million USD | 102.804% |
| Neogen Corporation | 735.62 Million USD | 101.026% |
| Inotiv, Inc. | 382.14 Million USD | 101.975% |
| Natera, Inc. | -200.1 Million USD | 96.228% |
| OpGen, Inc. | 11.89 Million USD | 163.472% |
| OPKO Health, Inc. | 230.68 Million USD | 103.272% |
| Psychemedics Corporation | 334 Thousand USD | 2359.88% |
| Prenetics Global Limited | -43.33 Million USD | 82.583% |
| Prenetics Global Limited | -43.33 Million USD | 82.583% |
| Precipio, Inc. | -386 Thousand USD | -1855.44% |
| Personalis, Inc. | -8.02 Million USD | 5.909% |
| RadNet, Inc. | 1.14 Billion USD | 100.657% |
| Sera Prognostics, Inc. | -2.02 Million USD | -273.294% |
| Sotera Health Company | 2.02 Billion USD | 100.373% |
| Neuronetics, Inc. | 2.79 Million USD | 369.861% |
| Star Equity Holdings, Inc. | -15.33 Million USD | 50.786% |
| Star Equity Holdings, Inc. | -15.33 Million USD | 50.786% |
| Trinity Biotech plc | 63.73 Million USD | 111.843% |
| T2 Biosystems, Inc. | 33.8 Million USD | 122.325% |
| Twist Bioscience Corporation | -192.4 Million USD | 96.077% |
| Exagen Inc. | -12.77 Million USD | 40.902% |